南京醫藥(600713.SH):擬對江蘇華曉醫藥物流異地新建項目增加投資2900萬元
格隆匯 8 月 13日丨南京醫藥(600713.SH)公佈,2018年9月20日,公司第八屆董事會第三次會議審議通過《關於江蘇華曉醫藥物流有限公司異地新建物流中心項目的議案》,同意公司全資子公司江蘇華曉醫藥物流有限公司(“江蘇華曉”)異地新建物流中心,項目選址為江蘇省鹽城市鹽都新區吳抬路和海闊路交界處65413平方米土地(最終面積以土地證為準)。項目一期建築面積約38000平方米,總投資約人民幣1.5億元。該項目目前已完成土地購買,並取得建築規劃許可。
因政策調整、建築市場價格上漲、設施設備及其他費用的增加,經公司總裁辦公會審議通過,擬對江蘇華曉醫藥物流異地新建項目增加投資2900萬元,增加投資後一期項目總投資為1.79億元。項目用地面積調整為63624 平方米(最終面積以土地證為準),一期項目建築面積調整為43459平方米(增加5459平方米)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.